Exicure agrees to sell GPC-100 program assets to GPCRT Inc. for KRW 6.5 billion
The Delaware biotech will transfer rights tied to its burixafor program to the Korean buyer in a cash deal worth about $4.8 million.
SEC filing
1 story
The Delaware biotech will transfer rights tied to its burixafor program to the Korean buyer in a cash deal worth about $4.8 million.
SEC filing